Yifan Pharmaceutical announced on January 6 that Hefei Yifan Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for vitamin K1 injections approved and issued by the State Drug Administration on January 5, 2026. Vitamin K1 injections are suitable for preventing and treating vitamin K deficiency bleeding in infants. As of the disclosure date of this report, the company invested about 206.604 million yuan in the research and development of vitamin K1 injections.

Yifan Pharmaceutical announced on January 6 that Hefei Yifan Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for vitamin K1 injections approved and issued by the State Drug Administration on January 5, 2026. Vitamin K1 injections are suitable for preventing and treating vitamin K deficiency bleeding in infants. As of the disclosure date of this report, the company invested about 206.604 million yuan in the research and development of vitamin K1 injections.